CN101991573A - Corynoxeine and application of isomer thereof in preparing medicines - Google Patents
Corynoxeine and application of isomer thereof in preparing medicines Download PDFInfo
- Publication number
- CN101991573A CN101991573A CN2010102949319A CN201010294931A CN101991573A CN 101991573 A CN101991573 A CN 101991573A CN 2010102949319 A CN2010102949319 A CN 2010102949319A CN 201010294931 A CN201010294931 A CN 201010294931A CN 101991573 A CN101991573 A CN 101991573A
- Authority
- CN
- China
- Prior art keywords
- corynoxeine
- isomer
- purposes
- isocorynoxeine
- expanding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the traditional Chinese medicine field, and relates to corynoxeine and an application of an isomer of the corynoxeine in preparing medicines. In the invention, the results of animal experiments prove that the corynoxeine and the isomer thereof have the effects of expanding vessels and lowering blood pressure, and can be used for preparing the medicines for expanding the vessels and lowering the blood pressure; the corynoxeine and isocorynoxeine have the effects of expanding the vessels, lowering heart afterload, lightening heart burden and decreasing myocardial oxygen consumption, and can be used for preparing anti-angina pectoris medicines; the corynoxeine has the effects of negative myodynamia, directly decreasing the myocardial oxygen consumption, and doubly lowering the myocardial oxygen consumption; the corynoxeine and the isocorynoxeine have the effects of improving the ventricular muscle excited threshold and lowering the ventricular muscle contraction frequency, can be used for treating ventricular tachycardia, and can be used as a quality identification uncaria and tagged molecules of the ffective parts of the corynoxeine and the isocorynoxeine.
Description
Technical field
The invention belongs to the field of Chinese medicines, the effective ingredient and the new medicine use thereof that relate to the Chinese medicine Ramulus Uncariae Cum Uncis, be specifically related to corynoxeine and isomer thereof (isocorynoxeine) purposes in the preparation medicine, especially prepare the purposes in Altace Ramipril, medicament for expanding vascellum, antianginal drug or the antiventricular arrhythmics thing.
Background technology
Hypertension is the major disease that threatens human health, and its hazardness is the caused target organ damage of long-term hypertension, is that due to illness the hyperpietic disables and lethal basic reason.Studies show that, target organ damage often involves important organs such as the heart, kidney, and its mechanism comprises many separate action pathway, for example: 1, little blood vessel wall hypertrophy, plumpness in the target organ, its main cause is protopathy such as inductive vascular smooth muscle cell curing such as hypertension, diabetes; Show as the coronary artery luminal stenosis at heart, blood flow descends, and causes myocardial ischemia, even arrhythmia, myocardial infarction, heart failure take place; At kidney, it is narrow to show as afferent glomerular arteriole, brings out glomerular sclerosis then, and renal failure finally takes place the infringement renal function.2, small artery systolic and diastolic function disorder in the target organ causes blood supply small artery abnormal contraction in the internal organs, makes the decline of internal organs blood flow and causes the target organ ischemic lesions.3, protopathy is brought out matter fibroblast proliferation between target organ, secretes a large amount of extracellular matrixs then, be piled up in target organs such as the heart, kidney between in the matter, make it gradually fibrosis take place and lose its normal function.4, protopathy causes response to oxidative stress, discharges a large amount of oxygen-derived free radicals in vivo and target organ is caused damage.
Hypertension belongs to chronic disease, does not still have the radical cure method at present, and the patient needs lifelong medication, in order to the long-term control blood pressure.Present clinical many employing chemical synthetic drugs are main Altace Ramipril, and described antihypertensive drugs brings high blood pressure down by reducing cardiac pump function, reduction periphery and increase kidney water sodium excretion etc. respectively.Therefore, ideal antihypertensive drug should have very high long-term prescription safety.
Usually, the blood vessel medicament for expanding vascellum is a kind of common drug of classifying separately clinically, except the treatment of the hypertension (is the high Peripheral resistance type hypertension of feature as increasing with diastolic pressure) that is used for some type, medicament for expanding vascellum also can be by reducing Peripheral resistance, lightening heart load and be used for the treatment of heart failure.Mostly the medicament for expanding vascellum of clinical practice at present is occurring in nature non-existent chemical synthetic drug (it represents medicine is phentolamine etc.) originally.
Angina pectoris is to be caused acute myocardial ischemia and often with severe pain, as in time being alleviated, myocardium irreversible damage can be taken place then by coronary vasospasm, comprises myocardial infarction.Anginal essence is that the balance between myocardial blood flow and the myocardial oxygen consumption is destroyed.Antianginal drug is a clinical class important drugs that is used for first aid, the antianginal drug of using clinically mainly contains three classes at present, treat angina pectoriss from expanding peripheral blood vessel (reduce cardiac load, alleviate the heart burden, reduce myocardial oxygen consumption), reduction heart rate and myocardial contraction (give the negativity inotropic medicament and reduce myocardial oxygen consumption) and three kinds of approach such as coronary artery of expansion spasm respectively with this, its representative drugs is a nitroglycerin, expand the peripheral arterial blood vessel by directly acting on vascular smooth muscle, cardiac afterload is reduced; The also expansible vein of nitroglycerin (capacitance vessel), thus returned blood volume reduced, alleviate cardiac preload, myocardial oxygen consumption is reduced and the treatment angina pectoris.
The choice drug of clinical treatment ventricular arrhythmia is a lignocaine at present, and its main mechanism is to suppress ventricular tachycardia by the excited threshold value that improves ventricular muscle cell.Can cause acute heart failure and threat to life when ventricular arrhythmia is serious, tachycardia is divided into multiple different type according to clinical manifestation and mechanism, wherein a class is owing to ventricular muscle cell transmembrane potential instability, excited threshold value reduce caused chamber arrhythmia, bring out under the conditions such as ischemia, inflammation of being everlasting, threat to life when serious needs treatment in time.
In view of hyperpietic's large contingent, the complication that causes is more serious, and the patient is a long-term prescription, occurring in nature very likely gets up in the medium-term and long-term accumulation of natural environment after non-existent chemicals is discharged from human body originally, natural water body, soil etc. are polluted, even more serious is that nature still lacks microorganism, enzyme or other chemical substance that can make its degraded, finally forms huge potential environmental hazard.Modern medicine study shows that natural plants has its natural degraded system at occurring in nature, does not have and discharge the anxiety of accumulating behind the human body in natural environment.Therefore, excavate active ingredient of natural plant and prepare antihypertensive drug, also have eco-friendly characteristics.
Ramulus Uncariae Cum Uncis is the dry stem and branch with belt hook of Maguireothamnus speciosus Ramulus Uncariae Cum Uncis, Ramulus Uncariae macrophyllae, Ramulus Uncariae Cum Uncis, Uncaria sinensis (Oliv.) Havil. or stockless fruit Ramulus Uncariae Cum Uncis.Known Ramulus Uncariae Cum Uncis is sweet, cool.Return liver, pericardium channel, have heat clearing away, suppressing the hyperactive liver, the effect of dispelling wind and relieving convulsion is applicable to the hypertensive treatment of liver-Yang sthenia type.Clear and definite Ramulus Uncariae Cum Uncis effective ingredient is Ramulus Uncariae cum Uncis alkali and isorhynchophylline at present, the effect that they have blood vessel dilating, bring high blood pressure down.So far, the relevant Ramulus Uncariae Cum Uncis effective ingredient of Shang Weijian: corynoxeine (corynoxeine) and isomer thereof (isocorynoxeine, the report of expansion blood vessel isocorynoxeine), hypotensive effect and heart effect.
Summary of the invention
The objective of the invention is to overcome the deficiencies in the prior art, effective ingredient corynoxeine and the new purposes of isomer (isocorynoxeine) in the preparation medicine, the especially purposes in preparation Altace Ramipril, medicament for expanding vascellum, antianginal drug or antiventricular arrhythmics thing of Chinese medicine Ramulus Uncariae Cum Uncis are provided.
The molecular formula of corynoxeine of the present invention is C
22H
26N
2O
4, molecular weight is 382.45, molecular structural formula is:
The molecular formula of its isomer of corynoxeine of the present invention (isocorynoxeine) is C
22H
26N
2O
4, molecular weight is 382.45, molecular structural formula is:
The present invention confirms through zoopery, described corynoxeine and isocorynoxeine have the diastole effect to the Hypertensive Rats aortic annulus, have expansion peripheral blood vessel and faithless myocardium muscular strength, hypotensive activity, can be used for preparation preparation medicament for expanding vascellum and Altace Ramipril;
Described Ramulus Uncariae Cum Uncis effective ingredient corynoxeine and isocorynoxeine have blood vessel dilating, reduce the effect of cardiac afterload and reduction myocardial contraction, can reduce myocardial oxygen consumption, are used to prepare antianginal drug, especially can prepare the medicine of angina pectoris first aid;
Described corynoxeine has negative inotropic action, can be used for preparing anti-ventricular tachycardia medicine;
Described corynoxeine and isocorynoxeine, especially isocorynoxeine have the effect that improves the excited threshold value of ventricular muscles, can prepare the antiventricular arrhythmics thing.
Corynoxeine of the present invention and isocorynoxeine can be further used as the marker molecule (check standard substance) of identifying Ramulus Uncariae Cum Uncis and effective site thereof, can identify the quality of Ramulus Uncariae Cum Uncis effective site as long-acting blood pressure lowering and cardiovascular target-organ protection medicine exactly.
For the ease of understanding, below will describe in detail the present invention by specific embodiment.It needs to be noted that these descriptions only are exemplary descriptions, do not constitute limitation of the scope of the invention.According to the argumentation of this description, many variations of the present invention, change all are conspicuous concerning one of ordinary skill in the art.
Description of drawings
Fig. 1 shows that in the pre-shrunk blood vessel of phyenlephrinium corynoxeine (46.8 mg/ml) can cause vasodilation rapidly.
Fig. 2 is the statistical result bar diagram of the vasodilative effect of corynoxeine.
Fig. 3 shows that in the pre-shrunk blood vessel of phyenlephrinium isocorynoxeine (46.8 mg/ml) causes vasodilation rapidly.
Fig. 4 is the statistical result bar diagram of the vasodilative effect of isocorynoxeine.
Fig. 5 shows that corynoxeine reduces the contractility of Hypertensive Rats ventricle papillary muscles, and reduces the number of contractions of ventricle papillary muscles.
Fig. 6 shows that corynoxeine reduces the maximum initiatively contractility tension force of Hypertensive Rats ventricle papillary muscles.
Fig. 7 shows that corynoxeine reduces the maximum tension rate of climb of Hypertensive Rats ventricle papillary muscles.
Fig. 8 shows that corynoxeine increases the stimulation-contraction of Hypertensive Rats ventricle papillary muscles time delay.
Fig. 9 shows that the mechanical number of contractions that corynoxeine causes the electricity irritation of Hypertensive Rats ventricle papillary muscles reduces.
Figure 10 shows that isocorynoxeine increases the contractility of Hypertensive Rats ventricle papillary muscles, reduces the number of contractions of ventricle papillary muscles.
Figure 11 shows that isocorynoxeine increases the maximum initiatively contractility tension force of Hypertensive Rats ventricle papillary muscles.
Figure 12 shows that isocorynoxeine increases the maximum tension rate of climb of Hypertensive Rats ventricle papillary muscles.
Figure 13 shows that the mechanical number of contractions that isocorynoxeine causes the electricity irritation of Hypertensive Rats ventricle papillary muscles reduces.
Specific embodiment
The present invention is experimental subject with the spontaneous hypertensive rat, carries out expansion blood vessel, the negativity cardiac muscle muscular strength of Ramulus Uncariae Cum Uncis effective ingredient corynoxeine and isocorynoxeine and the pharmacological action experimentation that improves the excited threshold value of ventricular muscles respectively.
Embodiment 1 corynoxeine and isocorynoxeine are to the diastole effect of Hypertensive Rats aortic annulus
Get male spontaneous hypertensive rat, body weight 200-250g.Put to death after the Animal Anesthesia, the taking-up thoracic aorta places and fills gaseous mixture (95% O
2, 5% CO
2) in the nutritional solution, clean the inside and outside congestion of blood vessel, adipose connective tissue around removing with tweezers.The tremulous pulse bar is cut into the long vascular ring of about 5 mm, passes with two stainless steel silk hooks, move to the bath intracavity that adds 10 ml nutritional solutions in advance, and continue logical gaseous mixture, it is 37 ℃ that the constant temperature water pump is kept the interior temperature of bath.The composition of nutritional solution: NaCl 118 mmol/L, KCl 4.5 mmol/L, CaCl
22.5 mmol/L, MgSO
41.2 mmol/L, KH
2PO
41.0 mmol/L, NaHCO
327 mmol/L, glucose 10 mmol/L.A hook is fixed on the support, and another root is connected on the tonotransducer.Give basic tension force 2 g, balance 2 h, 30 min change one time of nutrition liquid, during need continuous adjustment of tonicity baseline make it stable.
Giving under the basic tension force 2g situation, adding Klorvess Liquid 100mM, 20min backward pull value is as 100% reference.Flushing, the stable blood vessel that makes recover the initial tension value, add phyenlephrinium 10
-6Mol/L begins dosing (corynoxeine or isocorynoxeine) when vasoconstriction to plateau; Matched group then adds isopyknic corresponding control solvent.The antiotasis signal is by transducer input SMUP-PC type bio signal processing system (Shanghai good dragon religion instrument factory) and MFLab200 bio signal processing system (Fudan University), and the time in sampling interval is 1ms, notes down continuously 2 hours.
Experimental result shows:
In the pre-shrunk blood vessel of phyenlephrinium, corynoxeine (46.8 mg/ml) can cause vasodilation (as shown in Figure 1) rapidly.
Promptly occur rapidly in the vasodilative effect of corynoxeine 10 minutes after dosing, its effect continues to exist always, 120 minutes experiment finishes when being, the statistical result showed of the vasodilative effect of corynoxeine in the experiment of every group of 5 samples, compare with corresponding matched group and to have statistical significant difference, P＜0.05(is as shown in Figure 2), show that corynoxeine can reduce Peripheral resistance and blood pressure by expanding blood vessel, can be used for preparing depressor; In addition, corynoxeine can reduce cardiac afterload by expanding blood vessel, can alleviate the heart burden, reduces myocardial oxygen consumption, is used to prepare antianginal drug; Also because its vasodilative effect appearance rapidly, can be used for preparing the antianginal first aid medicine.
In the pre-shrunk blood vessel of phyenlephrinium, isocorynoxeine (46.8 mg/ml) also can cause vasodilation (shown in Figure 3) rapidly; Fig. 4 has shown the statistical result of vasodilative effect in the experiment of every group of 5 samples of isocorynoxeine, show and compare with corresponding matched group and to have statistical significant difference (
P＜0.05, n=5).Promptly occur rapidly in the vasodilative effect of isocorynoxeine 10 minutes after dosing, its effect continues to exist always, 120 minutes experiment end when be.
The result shows that isocorynoxeine can reduce Peripheral resistance and blood pressure by expanding blood vessel, can be used for preparing depressor; Isocorynoxeine can reduce cardiac afterload by expanding blood vessel, can alleviate the heart burden, reduces myocardial oxygen consumption, is used to prepare antianginal drug; Because its vasodilative effect occurs can be used for preparing antianginal drug, especially anginal first aid medicine rapidly.
Embodiment 2 corynoxeines and isocorynoxeine are to the effect of negative inotropic action of Hypertensive Rats ventricle papillary muscles and the excited threshold value of raising
Get the male spontaneous hypertensive rat of body weight 200-250g, put to death the anesthesia back, and the taking-up heart places and fills gaseous mixture (95% O
2, 5% CO
2) in the nutritional solution, wash down congestion in the heart gently, cut off the right heart, cut off the left heart by the apex of the heart to aortic arch portion, isolate papillary muscles.Heart is opened the back and is launched fixing around it with pin, make the complete exposure of papillary muscles, prick by aortic arch place tendon with 0 trumpeter's art toe-in, same ligation is by the apex tendon, the line of papillary muscles one end is fixed on the support, and the line of the other end is fixed on the tonotransducer and makes muscle between two electrodes of support, moves to the bath intracavity that adds 10 ml nutritional solutions in advance, and continuing logical gaseous mixture, it is 37 ℃ that the constant temperature water pump is kept the interior temperature of bath.The composition of nutritional solution: NaCl 137 mmol/L, KCl 5.4 mmol/L, CaCl
22H
2O 1.8 mmol/L, MgCl6H
2O 1.05 mmol/L, NaH
2PO
46H
2O 0.43 mmol/L, NaHCO
312 mmol/L, glucose 10 mmol/L.Tonotransducer 0 is the low value calibration, and 1g tension force is high value calibration.Connect electrostimulator, stimulus frequency is 12 times/minute, and ripple is wide: 1ms.Laboratory gives certain basis tension force (preload) and increases gradually, and is stable until shrinkage amplitude, balance 2h, and 30 min change one time of nutrition liquid, begin dosing (corynoxeine or isocorynoxeine) after stablizing; Matched group then adds isopyknic corresponding control solvent.
The papillary muscles contraction signal is through transducer input SMUP-PC type bio signal processing system (Shanghai good dragon religion instrument factory) and MFLab200 bio signal processing system (Fudan University), and the time in sampling interval is 1ms, notes down continuously 2 hours.And by the analysis of MFLab200 bio signal processing system maximum initiatively contractility tension force, the maximum tension rate of climb (dT/dt
Max), stimulation-contraction time delay etc. index, and the mechanical number of contractions that causes of statistics electricity irritation.
Experimental result shows:
In the experiment of every group of 6 samples, corynoxeine can obviously reduce the contractility of Hypertensive Rats ventricle papillary muscles, and the number of contractions (as shown in Figure 5) of minimizing ventricle papillary muscles, further analyze original contraction record wherein, and the credit that takes statistics is analysed, the result shows, compares with matched group, and corynoxeine can obviously reduce the maximum initiatively contractility tension force of Hypertensive Rats ventricle papillary muscles, it acts on and adds 40 behind the corynoxeine, 50,70,80,90, reach statistically-significant difference in the time of 100,110 and 120 minutes
P＜0.05, n=6(as shown in Figure 6).
Fig. 7 has shown that corynoxeine also can make the maximum tension rate of climb of Hypertensive Rats ventricle papillary muscles reduce, and it reaches statistically-significant difference when acting on 40,50,60,70,80,90,100,110 and 120 minutes that add behind the corynoxeine,
P＜0.05, n=6(is as shown in Figure 9), show that corynoxeine can reduce the inherent contractility of rat ventricular muscles, have the isometric regulating action of negativity, can therefore reduce myocardial oxygen consumption, be used for allevating angina pectoris.
The result has shown that also corynoxeine also can make the stimulation-contraction of Hypertensive Rats ventricle papillary muscles increase time delay, compares with corresponding matched group to have statistical significant difference,
P＜0.05, n=6(as shown in Figure 8); The mechanical number of contractions that corynoxeine also can make the electricity irritation of Hypertensive Rats ventricle papillary muscles cause reduces, compares with corresponding matched group to have statistical significant difference,
P＜0.05, n=6; Show that corynoxeine can improve the excited threshold value of ventricular muscles, make ventricular muscle cell be difficult for to reduce the ventricular muscles contraction frequency because of electricity irritation produces contraction; Show that corynoxeine has the effect of anti-chamber arrhythmia, can be used for treating ventricular tachycardia (as shown in Figure 9), data show wherein is a little less than the effect of the anti-chamber of isocorynoxeine arrhythmia than corynoxeine is; In the experiment of every group of 6 samples, isocorynoxeine can obviously increase the contractility of Hypertensive Rats ventricle papillary muscles, but can reduce the number of contractions of ventricle papillary muscles; Illustrate that isocorynoxeine can not reduce myocardial oxygen consumption, but can suppress ventricular tachycardia (as shown in figure 10).
Further analyze original contraction record, and result's demonstration is analysed in the credit that takes statistics, compare with matched group, isocorynoxeine can obviously increase the maximum initiatively contractility tension force of Hypertensive Rats ventricle papillary muscles, and it acts on and adds 10,20 behind the isocorynoxeine, 30, reach statistically-significant difference in the time of 40,50 and 70 minutes, wherein, * represent to compare and have statistical significant difference with corresponding matched group
P＜0.05, n=6(as shown in figure 11);
Experimental result has shown that also isocorynoxeine can make the maximum tension rate of climb of Hypertensive Rats ventricle papillary muscles increase, it acts on and adds 10 behind the isocorynoxeine, 30, reach statistically-significant difference in the time of 40 and 50 minutes, compare with corresponding matched group and to have statistical significant difference
P＜0.05, n=6(is as shown in figure 12), confirm that described isocorynoxeine can increase the inherent contractility of rat ventricular muscles, have the isometric regulating action of positivity, therefore increase myocardial oxygen consumption; The mechanical number of contractions that isocorynoxeine can make the electricity irritation of Hypertensive Rats ventricle papillary muscles cause reduces, and it is compared with corresponding matched group has statistical significant difference,
P＜0.05, n=6(as shown in figure 13), show that isocorynoxeine can improve the excited threshold value of ventricular muscles, make ventricular muscle cell be difficult for producing contraction because of electricity irritation, can reduce the ventricular muscles contraction frequency, show that isocorynoxeine has the effect of anti-chamber arrhythmia, can be used for the treatment of ventricular tachycardia.
Confirm according to this experimental result,
1, Ramulus Uncariae Cum Uncis effective ingredient corynoxeine has the pharmacological action of expanding blood vessel, negativity cardiac muscle muscular strength and improving the excited threshold value of ventricular muscles, reduction ventricular muscles contraction frequency, can reduce peripheral vascular resistance and myocardial oxygen consumption.According to its pharmacological action characteristics, corynoxeine can be used for preparing Altace Ramipril, medicament for expanding vascellum, antianginal drug and antiventricular arrhythmics thing.
2, isocorynoxeine then has the pharmacological action of expanding blood vessel and improving the excited threshold value of ventricular muscles, reduction ventricular muscles contraction frequency.According to its pharmacological action characteristics, isocorynoxeine can be used for preparing Altace Ramipril, medicament for expanding vascellum, antianginal drug and antiventricular arrhythmics thing.But because isocorynoxeine does not have negativity cardiac muscle myodyamia effect, can not directly act on cardiac muscle reduces its oxygen consumption, its antianginal effect only can produce by reducing cardiac afterload, its antianginal effect is than weak (corynoxeine has and both directly acts on the effect that cardiac muscle reduces its oxygen consumption, expands peripheral blood vessel again, reduces the dual function of cardiac afterload) of corynoxeine.In addition, the anti-ventricular arrhythmia effect of corynoxeine is also strong than isocorynoxeine.
Corynoxeine of the present invention and isocorynoxeine can be used as the marker molecule (check standard substance) of Quality Identification Ramulus Uncariae Cum Uncis and effective site (comprising the Ramulus Uncariae Cum Uncis effective site described in the Chinese patent 200610116517.2) thereof.
Claims (10)
1. corynoxeine and isomer thereof are in the purposes of preparation in the Altace Ramipril;
The molecular formula of described corynoxeine is C
22H
26N
2O
4, molecular weight is 382.45, molecular structural formula is:
The molecular formula of its isomer of described corynoxeine (isocorynoxeine) is C
22H
26N
2O
4, molecular weight is 382.45, molecular structural formula is:
。
2. corynoxeine and isomer thereof are in the purposes of preparation in the medicament for expanding vascellum.
3. corynoxeine and isomer thereof are in the purposes of preparation in the antianginal drug.
4. corynoxeine and isomer thereof the purposes in preparation antiventricular arrhythmics thing.
5. by the purposes of claim 1, it is characterized in that described corynoxeine and isomer thereof bring high blood pressure down by expansion peripheral blood vessel and faithless myocardium muscular strength.
6. by the purposes of claim 3, it is characterized in that described corynoxeine and isomer thereof reduce cardiac afterload by expanding blood vessel, reduce the myocardial oxygen consumption antianginal.
7. by the purposes of claim 3, it is characterized in that described corynoxeine and isomer thereof are by reducing myocardial oxygen consumption, allevating angina pectoris.
8. by the purposes of claim 3, it is characterized in that described antianginal drug is the antianginal first aid medicine.
9. by the purposes of claim 4, it is characterized in that described corynoxeine and isomer thereof improve the excited threshold value of ventricular muscles, reduce ventricular muscles contraction frequency, anti-ventricular tachycardia.
10. corynoxeine and isomer thereof are identified purposes in the marker molecule of Ramulus Uncariae Cum Uncis and effective site thereof in preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102949319A CN101991573A (en) | 2010-09-28 | 2010-09-28 | Corynoxeine and application of isomer thereof in preparing medicines |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102949319A CN101991573A (en) | 2010-09-28 | 2010-09-28 | Corynoxeine and application of isomer thereof in preparing medicines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101991573A true CN101991573A (en) | 2011-03-30 |
Family
ID=43782652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010102949319A Pending CN101991573A (en) | 2010-09-28 | 2010-09-28 | Corynoxeine and application of isomer thereof in preparing medicines |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101991573A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103417537A (en) * | 2013-08-30 | 2013-12-04 | 苏州天南星生物科技有限公司 | Purpose of dehydrogenation hirsutine |
| CN103432122A (en) * | 2013-08-30 | 2013-12-11 | 苏州天南星生物科技有限公司 | Application of isocorynoxeine in preparation of antihypertensive drugs |
| CN110664882A (en) * | 2018-07-02 | 2020-01-10 | 华东师范大学 | Composition containing rhynchophylline and skin care application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101342259A (en) * | 2008-06-18 | 2009-01-14 | 沈阳药科大学 | Method for extracting alkaloid valid target from hooked uncaria leaf, with hook stem branch or full grass and uses thereof |
-
2010
- 2010-09-28 CN CN2010102949319A patent/CN101991573A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101342259A (en) * | 2008-06-18 | 2009-01-14 | 沈阳药科大学 | Method for extracting alkaloid valid target from hooked uncaria leaf, with hook stem branch or full grass and uses thereof |
Non-Patent Citations (3)
| Title |
|---|
| MITSUTOSHI YUZURIHARA ET AL: "Geissoschizine methyl ether, an indole alkaloid extracted from Uncariae Ramulus et Uncus, is a potent vasorelaxant of isolated rat aorta", 《EUROPEAN JOURNAL OF PHARMACOLOGY》 * |
| 王礼振等编: "《钙拮抗剂的临床应用》", 30 June 1988, 中国医药科技出版社 * |
| 罗国海主编: "《天然药物学》", 31 August 2004, 郑州大学出版社 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103417537A (en) * | 2013-08-30 | 2013-12-04 | 苏州天南星生物科技有限公司 | Purpose of dehydrogenation hirsutine |
| CN103432122A (en) * | 2013-08-30 | 2013-12-11 | 苏州天南星生物科技有限公司 | Application of isocorynoxeine in preparation of antihypertensive drugs |
| CN110664882A (en) * | 2018-07-02 | 2020-01-10 | 华东师范大学 | Composition containing rhynchophylline and skin care application thereof |
| CN110664882B (en) * | 2018-07-02 | 2021-12-07 | 华东师范大学 | Composition containing rhynchophylline and skin care application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ward et al. | Activation and inflammation of the venous endothelium in vein graft disease | |
| Bosch et al. | Evolution in the understanding of the pathophysiological basis of portal hypertension: how changes in paradigm are leading to successful new treatments | |
| CN104804051B (en) | A kind of Acegastrodine derivative and preparation method thereof, preparation and application | |
| CN101011413B (en) | Use of hydrogen sulfide and its donor sodium hydrosulfide in the production of medicaments | |
| CN107734967A (en) | Calcium ion sensing needle is adjusted in the transplantable heart of acquisition | |
| CN108348481A (en) | Medicinal application of the dammara alkyl compound in treatment myocardial hypertrophy and pulmonary hypertension | |
| CN101991573A (en) | Corynoxeine and application of isomer thereof in preparing medicines | |
| Zhang et al. | Myocardial bridge bypass graft: a novel surgical procedure for extensive myocardial bridges | |
| CN101768145A (en) | Nitric oxide-donating chrysin derivatives, preparation method thereof, medical use thereof | |
| Zhang et al. | Intramyocardial injection of tannic acid attenuates postinfarction remodeling: a novel approach to stabilize the breaking extracellular matrix | |
| Onorati et al. | Troponin I and lactate from coronary sinus predict cardiac complications after myocardial revascularization | |
| Lyons et al. | Glucocorticoid administration reduces cardiac dysfunction after brain death in pigs | |
| WO2018152996A1 (en) | Use of nadph in preparation of medicine for treating cardiac hypertrophy and heart failure | |
| CN110478351A (en) | The new application of more target action compound X7 | |
| CN104513207A (en) | Benzyl alcohol ether compound, preparation method, preparation and application thereof | |
| CN104341358B (en) | A kind of compound and preparation method thereof and application | |
| CN104059154B (en) | A kind of new natriuretic peptide chimera C with heart failure resistance effectNAAC | |
| CN109288848A (en) | Prostaglandin E1 methyl esters is preparing the application in vasodilator drug | |
| Braunwald et al. | Protection of the ischemic myocardium | |
| CN111297848B (en) | Application of kaempferol and analogues thereof | |
| van Bragt et al. | Dynamic regulation of atrial coronary blood flow in healthy adult pigs | |
| CN103356637B (en) | Chaetocin is preparing the application in prevention and therapy cardiotropic formulation | |
| CN103083323A (en) | Application of fasudil hydrochloride in preparation of medicament for promoting in-vivo survival and repair of mesenchymal stem cells and preparation of fasudil hydrochloride | |
| CN104739851A (en) | New application of icariin, or icariin derivatives or icariin salt | |
| CN104434940A (en) | Application of panax japonicus IV a in prevention and treatment of cardiovascular disease and complication of cardiovascular disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20110330 |